Eli Lilly Signs $2.75B Deal to Bring AI-Developed Drugs to the Global Market
Eli Lilly has signed a $2.75 billion deal with Insilico Medicine to commercialize AI-developed therapies globally.
Eli Lilly has signed a $2.75 billion deal with Insilico Medicine to commercialize AI-developed therapies globally.
NVIDIA and Eli Lilly are creating a $1 billion AI co-innovation lab to accelerate drug discovery. The lab will integrate AI, biomedical data, and robotics to transform medicine development.